Alector (ALEC) Amortization of Deferred Charges (2025 - 2026)
Alector's (ALEC) quarterly Amortization of Deferred Charges came in at $81000.0 in Q2 2026, up 14.08% year-over-year from $71000.0 in Q2 2025, and up 3.85% quarter-over-quarter from $78000.0 in Q1 2026.
Powered by 
Analysis
Alector (ALEC) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends
Alector (ALEC) has reported Amortization of Deferred Charges for 2 consecutive years, with $81000.0 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 14.08% year-over-year to $81000.0 in Q2 2026; TTM through Jun 2026 was $312000.0, a 122.86% increase from a year earlier, with the FY2025 full-year figure at $293000.0, changed N/A from the prior year.
- Amortization of Deferred Charges was $81000.0 for Q2 2026 at Alector, up from $78000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $81000.0 in Q2 2026 and troughed at $69000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 81,000.00 |
| Mar 31, 2026 | 78,000.00 |
| Dec 31, 2025 | 78,000.00 |
| Sep 30, 2025 | 75,000.00 |
| Jun 30, 2025 | 71,000.00 |
| Mar 31, 2025 | 69,000.00 |